| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/22/2009 | WO2009012486A1 Varicella zoster virus-virus like particles (vlps) and antigens |
| 01/22/2009 | WO2009012460A1 Survivin peptides as cancer vaccines |
| 01/22/2009 | WO2009012268A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | WO2009012256A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | WO2009012166A1 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis |
| 01/22/2009 | WO2009012156A2 Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders |
| 01/22/2009 | WO2009011941A2 Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| 01/22/2009 | WO2009011912A1 A composition for treating hiv comprising virus-like particles |
| 01/22/2009 | WO2009011782A2 METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| 01/22/2009 | WO2009011707A1 Mutated e. coli heat-labile enterotoxin |
| 01/22/2009 | WO2009011413A1 Production and use of epitope-tagged hepatitis c virus particle |
| 01/22/2009 | WO2009010874A2 Preprocalcitonin antigen t epitopes |
| 01/22/2009 | WO2009010769A1 Pharmaceutical compositions comprising nucleic acids encoding constitutively active toll-like receptors. |
| 01/22/2009 | WO2009010614A1 Use of a new isolate of neospora caninum for the development of diagnostic tests and for preparation of products for treatment and prevention of the infection caused by neospora |
| 01/22/2009 | WO2009010296A2 Antibodies against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites thereof |
| 01/22/2009 | WO2009010290A2 Engineered anti-alpha v- integrin hybrid antibodies |
| 01/22/2009 | WO2009010228A1 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/22/2009 | WO2009009935A1 Replication-deficient recombinant virus, pharmaceutical composition comprising the same and the uses thereof |
| 01/22/2009 | WO2009009892A1 Engineered scfv against bovine herpes virus type i |
| 01/22/2009 | WO2009009883A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | WO2009009882A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | WO2009009881A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | WO2009009876A1 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
| 01/22/2009 | WO2008144763A3 Antibodies to il-6 and use thereof |
| 01/22/2009 | WO2008143676A4 Detoxified pneumococcal neuraminidase and uses thereof |
| 01/22/2009 | WO2008142303A3 Use of an anti-cxcr4 antibody for treating cancer |
| 01/22/2009 | WO2008122811A3 Adenoviral vectors encoding a pathogen or tumour antigen |
| 01/22/2009 | WO2008122769A3 Adenoviral vector encoding malaria antigen |
| 01/22/2009 | WO2008121876A3 Non-fucosylated antibodies |
| 01/22/2009 | WO2008121160A3 Optimized antibodies that target cd5 |
| 01/22/2009 | WO2008116937A3 Nucleic acids |
| 01/22/2009 | WO2008113916A9 Pharmaceutical composition containing antibodies directed against the herv-w envelope |
| 01/22/2009 | WO2007126959A8 Methods and compositions for inducing an immune response to hiv and models for testing |
| 01/22/2009 | WO2007126816A3 Methods and compositions for vaccination of poultry |
| 01/22/2009 | US20090023900 Anti-AlphaVBeta3 Recombinant Human Antibodies, Nucleic Acids Encoding Same |
| 01/22/2009 | US20090023663 Thymosin beta 4 compositions and methods |
| 01/22/2009 | US20090023224 Vascular endothelial growth factor 2 |
| 01/22/2009 | US20090023160 Antibodies specific for CYP1B1 |
| 01/22/2009 | US20090023152 Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 01/22/2009 | US20090023147 Diagnostics and therapeutics for osteoporosis |
| 01/22/2009 | US20090022769 Medical Devices Comprising Polymeric Drug Delivery Systems With Drug Solubility Gradients |
| 01/22/2009 | US20090022763 Animal product free media and processes for obtaining a botulinum toxin |
| 01/22/2009 | US20090022762 Polyvalent influenza virus-like particle (VLP) compositions |
| 01/22/2009 | US20090022761 Enhancement of Immune Response to Vaccine by Interferon Alpha |
| 01/22/2009 | US20090022760 Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants |
| 01/22/2009 | US20090022759 Adenovirus vector and method to manipulate the adenovirus genome |
| 01/22/2009 | US20090022756 Recombinant F1-V Plague Vaccine |
| 01/22/2009 | US20090022755 Vaccines against chlamydial infection |
| 01/22/2009 | US20090022754 Construction of recombinant immunodominant Rickettsia typhi proteins; using methylated or unmethylated recombinant OmpB fragments in immunoassays for detection of exposure to Rickettsia typhi |
| 01/22/2009 | US20090022753 Surface proteins of streptococcus pyogenes |
| 01/22/2009 | US20090022752 Recovering the protein expressed by open reading frame 2 from porcine circovirus type 2; provide immunogenic composition that comprises PCV2 ORF2 proteins and that are highly stable over a period of 24 months; lung lesions, nasal shedding, cough, diarrhea, |
| 01/22/2009 | US20090022751 Pcv2 immunogenic compositions and methods of producing such compositions |
| 01/22/2009 | US20090022750 Pcv2 immunogenic compositions and methods of producing such compositions |
| 01/22/2009 | US20090022749 Recovering the protein expressed by open reading frame 2 from porcine circovirus type 2; provide immunogenic composition that comprises PCV2 ORF2 proteins and that are highly stable over a period of 24 months |
| 01/22/2009 | US20090022748 Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| 01/22/2009 | US20090022747 B7-h3 and b7-h4, novel immunoregulatory molecules |
| 01/22/2009 | US20090022746 Complexes for transferring nucleic acids into cells |
| 01/22/2009 | US20090022745 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 01/22/2009 | US20090022744 Modified Fc molecules |
| 01/22/2009 | US20090022743 Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells |
| 01/22/2009 | US20090022742 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 01/22/2009 | US20090022741 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging |
| 01/22/2009 | US20090022740 Targetting slow-growing, relatively mutationally-spared cancer; one-step genetic switches; antiproliferative agents; magnetic resonance imaging |
| 01/22/2009 | US20090022739 MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR ALPHA (tnf-ALPHA) AND TREATING HUMAN DISEASE OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-ALPHA |
| 01/22/2009 | US20090022738 Multispecific deimmunized CD3-binders |
| 01/22/2009 | US20090022737 Aldos as modifiers of the igf pathway and methods of use |
| 01/22/2009 | US20090022736 Monoclonal Antibodies That Specifically Bind To And Neutralize Bacillus Anthracis Toxin, Compositions, And Methods Of Use |
| 01/22/2009 | US20090022735 Receptor Binding Polypeptides |
| 01/22/2009 | US20090022734 Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| 01/22/2009 | US20090022733 Methods for treating Disease with an IL-1R antibody |
| 01/22/2009 | US20090022732 Crystal of a cytochrome-ligand complex and methods of use |
| 01/22/2009 | US20090022731 Arthritis-associated B cell gene expression |
| 01/22/2009 | US20090022730 Methods and compositions for assessing acute rejection |
| 01/22/2009 | US20090022729 Methods and compositions for treating cardiac dysfunctions |
| 01/22/2009 | US20090022728 Methods of treating ophthalmic diseases |
| 01/22/2009 | US20090022727 Injectable, nonaqueous suspension with high concentration of therapeutic agent |
| 01/22/2009 | US20090022726 Method of using il6 antagonists with proteasome inhibitors |
| 01/22/2009 | US20090022725 antagonist antibody that blocks binding of IL-17; degenerative cartilaginous disorders and other inflammatory diseases |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022723 Anti-il-tif antibodies and methods of using in inflammation |
| 01/22/2009 | US20090022722 Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| 01/22/2009 | US20090022721 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 01/22/2009 | US20090022720 Conjugate of an antibody against CD4 and antifusogenic peptides |
| 01/22/2009 | US20090022719 Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-IL-6 receptor antibody administration |
| 01/22/2009 | US20090022718 Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof |
| 01/22/2009 | US20090022717 Antibodies that bind cxcr7 epitopes |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022715 Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022713 Anti-pro87299 antibodies |
| 01/22/2009 | US20090022712 Compositions and Methods for Inhibiting Leukocyte Function |
| 01/22/2009 | US20090022711 Methods of modulating cell death based on the bit-1/aes regulatory pathway |
| 01/22/2009 | US20090022710 Nuclear factor of activated t cells receptor |
| 01/22/2009 | US20090022709 Control of sorbose utilization genes and uses thereof |
| 01/22/2009 | US20090022708 Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| 01/22/2009 | US20090022707 contacting target cells with a therapeutic quantity of a soluble antibody that specifically binds tumor necrosis factor-related apoptosis inducing ligand receptor(TRAIL) DR5, and contacting target cells with a therapeutic agent |
| 01/22/2009 | US20090022689 C4-spiro-pyrrolidine antivirals |
| 01/22/2009 | US20090022683 Biodegradable and Thermosensitive Poly(Organophosphazene) Hydrogel, Preparation Method Thereof and Use Thereof |
| 01/22/2009 | US20090022669 Compositions for protein delivery via the pulmonary route |
| 01/22/2009 | US20090022667 METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 |